CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
CITIUS ONCOLOGY, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.71−0.06 (-7.49%)
Close on Oct 19, 2026
- Market cap
- $76.65M
- P/E (TTM)
- –
- Dividend yield
- –
Citius Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Market Cap | $66.05M | $166.30M |
| Enterprise Value | $55.90M | $88.19M |
| PB Ratio | 1.64 | 2.03 |
| P/TBV Ratio | 1.64 | 2.29 |
Income (trailing twelve months)
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Operating Income | -$47.29M | -$21.40M |
| Pretax Income | -$45.87M | -$14.34M |
| Net Income | -$46.06M | -$22.46M |
| EBITDA | -$47.29M | -$16.91M |
| EPS (Diluted) | -$0.47 | -$0.83 |
Returns
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -126.6% | -53.2% |
| Return on Assets (ROA) | -45.2% | -40.9% |
| Return on Invested Capital (ROIC) | -119.3% | -32.4% |
| Return on Capital Employed (ROCE) | -88.7% | -38.1% |
Balance sheet
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $16.56M | $61.43M |
| Total Debt | $6.41M | $118.52M |
| Net Cash (Debt) | $10.15M | $15.35M |
| Net Cash Per Share | $0.11 | $0.66 |
| Equity (Book Value) | $40.39M | $49.09M |
| Book Value Per Share | $0.43 | $1.37 |
| Tangible Book Value | $40.39M | $23.52M |
| Working Capital | -$16.08M | $76.81M |
Financial position
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Current Ratio | 0.73 | 3.34 |
| Quick Ratio | 0.29 | 2.44 |
| Debt / Equity | 0.16 | 0.52 |
| Interest Coverage | -128.56 | -6.26 |
Dividends and yields
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Earnings Yield | -69.7% | -23.3% |
| Buyback Yield | -45.8% | -0.59% |
| Shareholder Yield | -45.8% | 0.00% |
Shares
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 92,981,200 | 58,127,000 |
| Shares Change (QoQ) | 13.7% | 0.54% |
| Float | 20,810,400 | 49,136,700 |
| Shares Held by Insiders | 77.6% | 11.6% |
| Shares Held by Institutions | 15.2% | 59.4% |
Taxes
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Income Tax | $189.92K | $79.87K |
Scores
| Measure | Citius Oncology | Industry median |
|---|---|---|
| Altman Z-Score | -2.32 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Citius Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.